Literature DB >> 8889411

Patient retention in mobile and fixed-site methadone maintenance treatment.

L Greenfield1, J V Brady, K J Besteman, A De Smet.   

Abstract

The retention of patients (n = 399) enrolled in mobile health services (MHS), a Baltimore outpatient mobile methadone treatment program, was compared to patient retention (n = 1588) in six Baltimore fixed-site programs. Mobile program patients were retained for a median of 15.53 months in treatment in comparison to 3.90 for fixed-site patients (n = 664) from the MHS served zip codes (MHSZIPS) and 6.27 for fixed-site patients (n = 924) from zip codes other than those served by MHS (OTHERZIPS), (P < 0.001). Using Cox regression, the characteristics of patients associated with earlier discharge were (1) higher number of arrests, (2) more frequent cocaine use and (3) lower family income. These predictors of shorter retention were generally more prevalent among patients from the MHS served zip codes. Therefore, the longer retention in treatment of MHS patients as compared to OTHERZIPS fixed-site program patients is even more striking. Consistent with these differences in retention, were finding in a prior study suggesting that the mobile program provided greater access to services in reducing patient transportation cost and travel time. Thus, mobile methadone maintenance treatment appears to be a useful means of providing services.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889411     DOI: 10.1016/0376-8716(96)01273-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  24 in total

1.  Access to publicly funded methadone maintenance treatment in two western states.

Authors:  Dennis Deck; Matthew J Carlson
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

2.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

3.  Willingness to pay for drug rehabilitation: implications for cost recovery.

Authors:  D Bishai; J Sindelar; E P Ricketts; S Huettner; L Cornelius; J J Lloyd; J R Havens; C A Latkin; S A Strathdee
Journal:  J Health Econ       Date:  2007-12-05       Impact factor: 3.883

4.  Pioneer in behavioral pharmacology: a tribute to Joseph V. Brady.

Authors:  James E Barrett
Journal:  J Exp Anal Behav       Date:  2008-11       Impact factor: 2.468

5.  Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Authors:  Michael S Gordon; Frank J Vocci; Terrence T Fitzgerald; Kevin E O'Grady; Charles P O'Brien
Journal:  Contemp Clin Trials       Date:  2016-12-20       Impact factor: 2.226

Review 6.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

7.  Predictors of methadone treatment retention from a multi-site study: a survival analysis.

Authors:  Sharon M Kelly; Kevin E O'Grady; Shannon Gwin Mitchell; Barry S Brown; Robert P Schwartz
Journal:  Drug Alcohol Depend       Date:  2011-02-09       Impact factor: 4.492

8.  Drug abuse treatment success among needle exchange participants.

Authors:  R Brooner; M Kidorf; V King; P Beilenson; D Svikis; D Vlahov
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 9.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

10.  Joseph v. Brady: synthesis reunites what analysis has divided.

Authors:  Travis Thompson
Journal:  Behav Anal       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.